Skip to content


Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer

Waltham, Mass. – October 24, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio’s chemistry, manufacturing and control (CMC)-related activities.

“We are thrilled to welcome Saul to the Q32 Bio team to take the helm of our manufacturing operations,” said Jodie Morrison, who has assumed the role of Q32’s long-term Chief Executive Officer from her previous position as acting CEO. “Saul is a proven CMC strategy and operations leader who has guided CMC and nonclinical teams across numerous therapeutic areas for both small molecule and biologic assets, at established pharmaceutical companies and nascent start-ups. With his deep leadership experience across manufacturing functions, Saul will be instrumental as we continue to drive the clinical development of our biologic therapeutics, which aim to rebalance immunity for patients with severe autoimmune and inflammatory diseases.”

“I am delighted to join Q32 Bio at this exciting stage of the Company’s growth,” said Dr. Fink. “The team is advancing an innovative scientific approach and is sincerely committed to delivering meaningful treatments. I look forward to collaborating with this talented group, contributing my expertise to advance our therapies and bring them to patients with critical unmet needs.”

Prior to joining Q32 Bio, Dr. Fink served as Senior Vice President, Pharmaceutical and Nonclinical Development at Normunity, where he led the CMC and nonclinical teams. Previously, he was Vice President of Pharmaceutical Development and Interim Lead of Nonclinical Development at Goldfinch Bio, leading manufacturing and nonclinical development of both small molecules and biologics. Prior, Dr. Fink spent 26 years at Bristol-Myers Squibb, partnering with executive management to define CMC strategy, drive business transformations and optimize manufacturing operations. Dr. Fink received his Ph.D. in Physical/Analytical Chemistry from the University of Houston, and his B.S. in Chemistry from Millersville University where he is currently a member of the Council of Trustees as part of his extensive service on not-for-profit and local government boards. He also serves as a scientific advisory board member for Intrommune Therapeutics.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.

The Company’s most advanced program, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function and is being developed in collaboration with Horizon Therapeutics for the treatment of autoimmune diseases, including Phase 2 trials in both atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

Q32 Bio’s lead program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has recently completed a first-in-human, Phase 1, ascending dose (SAD/MAD) clinical study of ADX-097 in healthy volunteers. For more information, please visit

Q32 Bio Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners